Zura Bio Limited
HealthcareNASDAQ:ZURA · NASDAQ Capital Market
+$0.12 today
Vol 0.47M · Avg 0.73M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-67.6%
avg -23.7%
ROIC
-74.1%
avg 264.4%
ROA
-60.2%
avg -126.5%
Analysis
ROA is currently the strongest return metric at -60.2% versus its period average of -126.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kimberly Ann Davis | Chief Operating Officer, Chief Legal Officer & Corporate Secretary | $807,203.00 | — | 58 | $425,700.00 | 0.65% |
Kiran Nistala MBBS | Chief Medical Officer & Head of Development | $691,153.00 | — | 53 | $340,900.00 | 0.52% |
Eric Hyllengren | Chief Financial Officer | $462,001.00 | — | 51 | $340,900.00 | 0.52% |
Sandeep C. Kulkarni | Co-Founder, CEO & Director | $55,550.00 | — | 44 | $894,000.00 | 1.37% |
Sandeep Chidambar Kulkarni | Co-Founder, CEO & Director | $55,550.00 | — | 44 | $894,000.00 | 1.37% |
Someit Sidhu | Co-Founder & Director | $46,676.00 | — | 36 | $51,000.00 | 0.08% |
Marlyn Mathew | VP of Finance & Accounting and Principal Financial & Accounting Officer | — | — | 42 | — | — |
Theresa Lowry | Chief Human Resources Officer | — | — | 52 | — | — |
Gary Whale | Chief Technology Officer | — | — | 52 | $263,000.00 | 0.40% |
Muzammil Mustufa | Chief Business Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$12.50M
Sells
0
$0.00
Net Sentiment
+$12.50M
Net buying
Most Active
AI Biotechnology LLC
1 transactions
Analysis
Insiders reported 1 buys worth $12.50M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $12.50M. AI Biotechnology LLC was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Assembly Biosciences, Inc.
NASDAQ:ASMB
$364.90M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$284.66M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$245.42M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$211.13M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$198.11M
Immuneering Corporation
NASDAQ:IMRX
$152.11M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$118.59M
Pyxis Oncology, Inc.
NASDAQ:PYXS
$111.51M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$85.08M
Who manages ZURA?
Zura Bio Limited (ZURA) lists 10 active executives. The top listed executive is Marlyn Mathew, VP of Finance & Accounting and Principal Financial & Accounting Officer.
Are ZURA insiders buying or selling?
Recent insider activity shows net buying of $55.11M.
Explore More
Continue the stock analysis
Jump to another research area for this company.